Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Andrology. 2024 Feb;12(2):247-258. doi: 10.1111/andr.13403. Epub 2023 Feb 17.
Premature ejaculation (PE), despite its wide prevalence, is largely underdiagnosed and undertreated. Being a multifactorial dysfunction with strong cultural characteristics, PE requires skillful attitudes in the psychosexological support, necessary to manage the patient's and the couple's expectations, as well as in the medical treatment. Dapoxetine is a short-acting selective serotonin reuptake inhibitor approved for use in lifelong and acquired PE in a number of countries. Opinions, not always generated by the evidence-based medicine, impacted the attitudes of Western andrologists, as a nocebo effect which produced a drug's Waterloo, characterized by low prescription rates much more built on the patients' and doctors' expectations than on costs, side effects, and efficacy. In the present study, we retrospectively reviewed real-life data from eight Andrology and Sexual Medicine Public Centers in China to assess the prevalence of PE among attending patients, its association with erectile dysfunction, its subtype, and the proposed treatments. In 2019, among 156,486 patients coming to the centers, 32,667 visits having PE as the chief complaint were performed (20.9%). Almost all patients received treatment prescriptions (32,641 patients, 99.92%); 23,273 patients came back for a follow-up visit in the subsequent 12 months (71.2% of those who initially received treatment). Dapoxetine, either alone or in combination with another therapy, was the most prevalent treatment, prescribed to 22,767 patients (69.7% of treated patients), followed by traditional Chinese medicine (TCM) (39.4%). At follow-up, 8174 patients were unsatisfied with treatment, and a new treatment was proposed (35.12%). Dapoxetine was the best treatment, with an overall 27.1% switching rate when used either alone or in combination: Although the switching rate for Dapoxetine alone was 44.2%, the association of the same drug with psychotherapy resulted in much lower rates (19.5%) and reached a minimum of 12% when also combined with TCM demonstrating how cultural aspects and medical attitudes may dramatically impact on the therapy of a multifaceted, complex, and culture-grounded sexual symptom such as PE. In conclusion, taking switching rates as surrogate markers of treatment failure, this real-life study-the largest in the field-shows that in a more patient-oriented (as in Chinese medical culture), and less symptom-oriented (as in Western medical attitudes), Dapoxetine is a successful treatment for PE patients, with higher reliability when used alone or as part of combined and integrated therapies.
早泄(PE)尽管普遍存在,但很大程度上被漏诊和治疗不足。PE 是一种具有强烈文化特征的多因素性功能障碍,需要在心理-性支持方面具备专业技能,以管理患者和伴侣的期望,同时还需要进行医学治疗。达泊西汀是一种短效选择性 5-羟色胺再摄取抑制剂,已在多个国家获批用于治疗终身和获得性 PE。由于缺乏循证医学证据,一些观点影响了西方男科医生的态度,产生了一种“反安慰剂效应”,导致该药在西方市场的失败,其处方率较低,更多地建立在患者和医生的期望上,而不是成本、副作用和疗效上。在本研究中,我们回顾性分析了中国 8 家男科和性医学公共中心的真实数据,评估了就诊患者中 PE 的患病率、PE 与勃起功能障碍的关系、PE 亚型以及提出的治疗方法。2019 年,在前来中心就诊的 156486 名患者中,有 32667 名(20.9%)患者以 PE 为主诉就诊。几乎所有患者都接受了治疗处方(32641 名患者,99.92%);其中 23273 名患者在随后的 12 个月内进行了复诊(初次接受治疗的患者中有 71.2%复诊)。达泊西汀单独或与其他治疗方法联合应用是最常见的治疗方法,共为 22767 名患者开具了处方(接受治疗患者的 69.7%),其次是中药(TCM)(39.4%)。复诊时,8174 名患者对治疗不满意,并提出了新的治疗方案(35.12%)。达泊西汀是最佳治疗方法,单独或联合使用时总体转换率为 27.1%:虽然单独使用达泊西汀的转换率为 44.2%,但相同药物联合心理治疗的转换率则较低(19.5%),与 TCM 联合使用时转换率最低为 12%,这表明文化因素和医疗态度可能会对 PE 等多方面、复杂且具有文化基础的性症状的治疗产生显著影响。总之,以转换率作为治疗失败的替代指标,这项真实世界的研究(该领域最大规模的研究)表明,在以患者为中心(如中国医学文化)且较少关注症状(如西方医学态度)的情况下,达泊西汀是 PE 患者的一种成功治疗方法,单独使用或作为联合和综合治疗的一部分时,其可靠性更高。